Masato Maekawa

Prof. Dr. Masato Maekawa

orcid

Research Focus & Metrics

Academic Career Length

41Years (1986-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2001 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
YMYasuyuki Miyakura
Yasuyuki Miyakura
KSKokichi Sugano
Kokichi Sugano
FKFumio Konishi
Fumio Konishi
AIAkira Ichikawa
Akira Ichikawa
MMMasato Maekawa
Masato Maekawa
HNHideo Nagai
Hideo Nagai

1 November 1994 in Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism
Verified
Journal Article
Closed access
KKKazuo Kotani
Kazuo Kotani
MMMasato Maekawa
Masato Maekawa
TKTakashi Kanno
Takashi Kanno
AKAkira Kondo
Akira Kondo
NTNaoko Toda
Naoko Toda
MMMitsuhisa Manabe
Mitsuhisa Manabe

1 January 2010
Verified
Book Chapter
Closed access
YWYoshihisa Watanabe
Yoshihisa Watanabe
MMMasato Maekawa
Masato Maekawa

1 October 2013 in Molecular & Cellular Proteomics
Verified
Journal Article
Open access
PDF file
HKHari Kosanam
Hari Kosanam
IPIoannis Prassas
Ioannis Prassas
CCCaitlin C. Chrystoja
Caitlin C. Chrystoja
ISIreena Soleas
Ireena Soleas
ACAlison Chan
Alison Chan
EDEleftherios P Diamandis
Eleftherios P Diamandis
In pancreatic cancer, the incidence and mortality curves coincide. One major reason for this high mortality rate in pancreatic ductal adenocarcinoma (PDAC) patients is the dearth of effective diagnostic, prognostic, and disease-monitoring biomarkers. Unfortunately, existing tumor markers, as well as current imaging modalities, are not sufficiently sensitive and/or specific for early-stage diagnosis. There is, therefore, an urgent need for improved serum markers of the disease. Herein, we performed Orbitrap® mass spectrometry proteomic analysis of four PDAC tissues and their adjacent benign tissues and identified a total of 2190 nonredundant proteins. Sixteen promising candidates were selected for further scrutiny using a systematic scoring algorithm. Our preliminary serum verification of the top four candidates (DSP, LAMC2, GP73, and DSG2) in 20 patients diagnosed with pancreatic cancer and 20 with benign pancreatic cysts, showed a significant (p < 0.05) elevation of LAMC2 in pancreatic cancer serum. Extensive validation of LAMC2 in healthy, benign, and PDAC sera from geographically diverse cohorts (n = 425) (Japan, Europe, and USA) demonstrated a significant increase in levels in early-stage PDAC compared with benign diseases. The sensitivity of LAMC2 was comparable to CA19.9 in all data sets, with an AUC value greater than 0.85 in discriminating healthy patients from early-stage PDAC patients. LAMC2 exhibited diagnostic complementarity with CA19.9 by showing significant (p < 0.001 in two out of three cohorts) elevation in PDAC patients with clinically low CA19.9 levels.

20 October 2014 in British Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
YTYoshiki Tokura
Yoshiki Tokura
HYH. Yagi
H. Yagi
HYH. Yanaguchi
H. Yanaguchi
YMY. Majima
Y. Majima
AKA. Kasuya
A. Kasuya
HHHideo Hashizume
Hideo Hashizume

1 February 2004 in Clinical Gastroenterology and Hepatology
Verified
Journal Article
Closed access
YMYasuyuki Miyakura
Yasuyuki Miyakura
KSKokichi Sugano
Kokichi Sugano
TATakayuki Akasu
Takayuki Akasu
TYTeruhiko Yoshida
Teruhiko Yoshida
MMMasato Maekawa
Masato Maekawa
HNHideo Nagai
Hideo Nagai